Table of Contents Author Guidelines Submit a Manuscript
Case Reports in Dermatological Medicine
Volume 2017, Article ID 3194738, 5 pages
https://doi.org/10.1155/2017/3194738
Case Report

A Severe Case of Lymphomatoid Papulosis Type E Successfully Treated with Interferon-Alfa 2a

1Dermatology and Venereology Department, Akdeniz University Faculty of Medicine, Antalya, Turkey
2Pathology Department, Akdeniz University Faculty of Medicine, Antalya, Turkey
3Dermatology and Venereology Department, Ankara University Faculty of Medicine, Ankara, Turkey
4Dermatology and Venereology Department, Pamukkale University Faculty of Medicine, Denizli, Turkey

Correspondence should be addressed to Soner Uzun; moc.liamtoh@nuzunos

Received 14 January 2017; Revised 28 March 2017; Accepted 13 April 2017; Published 30 April 2017

Academic Editor: Henry Wong

Copyright © 2017 Aslı Bilgiç Temel et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Lymphomatoid papulosis (LyP) is a benign papulonodular skin eruption with histologic features of malignant lymphoma. A new variant of LyP which was termed “type E” was recently described with similar clinical and histological features to angiocentric and angiodestructive T-cell lymphoma. LyP type E is characterized with recurrent papulonodular lesions which rapidly turn into hemorrhagic necrotic ulcers and spontaneous regression by leaving a scar. None of the available treatment modalities affects the natural course of LyP. For therapy various modalities have been used such as topical and systemic steroids, PUVA, methotrexate, bexarotene, and IFN alfa-2b. Here we present a severe and devastating case with a very rare variant of LyP type E, which is, to our knowledge, the first case successfully treated with IFN alfa-2a. Now disease has been maintaining its remission status for six months.